Rolf Kaiser

Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter.

Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection.

Validity of PCR with emphasis on variable number of tandem repeat analysis.

Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.

Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.

Risk of hepatitis C after immunoadsorption.

Frequency of the 17-bp variable number of tandem repeat polymorphism in Turkish schizophrenic patients.

Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.

Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes.

Methods for optimizing antiviral combination therapies.

Tenofovir resistance and resensitization.

Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis.

Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia.

Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists.

Pharmacogenetics-based new therapeutic concepts.

Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.

Mtreemix: a software package for learning and using mixture models of mutagenetic trees.

Estimating HIV evolutionary pathways and the genetic barrier to drug resistance.

Antiemetic guidelines: are they being used?

Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non-inactivated or inactivated factor concentrates.

Learning multiple evolutionary pathways from cross-sectional data.

Computational methods for the design of effective therapies against drug resistant HIV strains.

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.

Basics of the virology of HIV-1 and its replication.

Bioinformatics approach to predicting HIV drug resistance.

Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing.

Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk.

Detection of bocavirus DNA in nasopharyngeal aspirates of a child with bronchiolitis.

Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART.

Functional domains of the human immunodeficiency virus type 1 Nef protein are conserved among different clades in Cameroon.

Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma.

Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient.

Severe pneumonia and human bocavirus in adult.

Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

A novel internally controlled real-time reverse transcription-PCR assay for HIV-1 RNA targeting the pol integrase genomic region.

Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance.

Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.

Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load <50 copies/ml.

Trends of prevalence of primary HIV drug resistance in Germany.

Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level.

Fifteen years of env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1.

Predicting HIV coreceptor usage on the basis of genetic and clinical covariates.

Bioinformatics prediction of HIV coreceptor usage.

Functional characterization of a -100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene.

Serotonin transporter gene and response to lithium augmentation in depression.

Selecting anti-HIV therapies based on a variety of genomic and clinical factors.

Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy.

Genotypic antiretroviral resistance testing for human immunodeficiency virus type 1 integrase inhibitors by use of the TruGene sequencing system.

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients.

Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database.

Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.

Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype.

Evolution of raltegravir resistance during therapy.

Kinetic binding analysis of aptamers targeting HIV-1 proteins by a combination of a microbalance array and mass spectrometry (MAMS).

[Resistance screening].

Seasonal influenza virus species in patient swab samples analyzed for the presence of the pandemic (H1N1) 2009 influenza virus.

V3 loop sequence space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV.

When and how to use maraviroc in HIV-infected patients.

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.

Only slight impact of predicted replicative capacity for therapy response prediction.

Short communication: selection of thymidine analogue resistance mutational patterns in children infected from a common HIV type 1 subtype G source.

Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates.

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients.

Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.

Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolates.

Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients.

Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120.

Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.

Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity.

Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.

Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition.

Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort.

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers.

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.

HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany.

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis.

APOBEC3G/F as one possible driving force for co-receptor switch of the human immunodeficiency virus-1.

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.

Severe human bocavirus infection, Germany.

Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors.

Endogenous or exogenous spreading of HIV-1 in Nordrhein-Westfalen, Germany, investigated by phylodynamic analysis of the RESINA Study cohort.

HIV-GRADE: A Publicly Available, Rules-Based Drug Resistance Interpretation Algorithm Integrating Bioinformatic Knowledge.

Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project.

Risk Factors Associated with Older Age in Treatment-Naive HIV-Positive Patients.

Epidemiology of Transmitted Drug Resistance in Chronically HIV-Infected Patients in Germany: The RESINA Study 2001-2009.

Efficacy of Antiretroviral Therapy Switch in HIV-Infected Patients: A 10-Year Analysis of the EuResist Cohort.

How Individual Can Personalized Antiretroviral Treatment Be? Deep Salvage in an HIV-1-Infected Patient.